Merck & Company Inc (MRK)vsProgyny Inc (PGNY)
MRK
Merck & Company Inc
$129.79
-0.44%
HEALTHCARE · Cap: $307.25B
PGNY
Progyny Inc
$31.37
+1.98%
HEALTHCARE · Cap: $2.50B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 4986% more annual revenue ($65.77B vs $1.29B). MRK leads profitability with a 13.6% profit margin vs 5.2%. MRK trades at a lower P/E of 35.6x. PGNY earns a higher WallStSmart Score of 50/100 (C-).
MRK
Hold50
out of 100
Grade: D+
PGNY
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.3%
Fair Value
$81.23
Current Price
$129.79
$48.56 premium
Intrinsic value data unavailable for PGNY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Earnings expanding 70.6% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
1.4% revenue growth
5.2% margin — thin
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : PGNY
The strongest argument for PGNY centers on EPS Growth, Debt/Equity, Altman Z-Score.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : PGNY
The primary concerns for PGNY are Revenue Growth, Profit Margin, Piotroski F-Score. A P/E of 41.5x leaves little room for execution misses.
Key Dynamics to Monitor
PGNY carries more volatility with a beta of 1.02 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (50/100 vs 50/100). Both earn "Hold" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Progyny Inc
HEALTHCARE · HEALTHCARE PLANS · USA
Progyny, Inc., a benefits management company, specializes in fertility benefits and family development solutions for employers in the United States. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?